Genenta Science (GNTA) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025
PR NewswireFeb 27 10:04 ET
Top Premarket Gainers
MT NewswiresFeb 25 07:36 ET
Is Genenta Science S.p.A. (GNTA) the Best Italian Stock to Buy in 2025?
Yahoo FinanceFeb 13 00:03 ET
Genenta Science Says Enhanced Partnership With AGC Biologics to Boost Cell Therapy Manufacturing
MT NewswiresJan 9 15:03 ET
Express News | Genenta Science Has Amended Its Partnership With AGC Biologics And Introduced An Exclusive GMP Suite At The AGC Biologics Cell And Gene Center Of Excellence In Milan To Manufacture Genenta's Cell Therapy Product
BenzingaJan 9 06:02 ET
Genenta Science Updates ATM Sales Agreement With New Agent
TipRanksDec 20, 2024 16:53 ET

Comments

Jaguar8

Jan 9 07:59

NEWS

$Genenta Science (GNTA.US)$
Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing
Thursday, 9th January at 6:00 am
MILAN and NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that it has strengthened its partnership with AGC Biologics, a global contract development and manufacturing organization (CDMO), by amending their Development and Master S...

1

Jaguar8

Oct 2, 2024 06:47

NEWS

$Genenta Science (GNTA.US)$
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
Genenta Science (NASDAQ: GNTA) has received approval from AIFA for a new Phase 1 clinical trial for metastatic Renal Cell Cancer (mRCC), expanding potential applications for its flagship product, Temferon™. This approval aligns with EMA standards. The company's ongoing TEM-GBM development program has completed a Phase 1 dose-ranging trial, confirming no dose-limiting toxicities across ...